Jharkhand man undergoes robot-assisted cementless knee surgery in Delhi, walks same day
Brij Kishor from Dhanbad in Jharkhand had been battling chronic knee pain and progressive joint damage for over eight years.
During this period, he sought treatment from local doctors, tried homoeopathic medicine and even travelled to Kolkata for medical consultations. Eventually, he came to Delhi, the patient told PTI.
On June 23, he underwent surgery at Max Super Speciality Hospital in Saket.
According to a statement issued by the hospital, he was diagnosed with severe osteoarthritis in both knees, along with complex deformities such as varus (bow-legged) and flexion (bent-knee) contractures. He had been unable to walk without support.
The surgery was led by Dr Sujoy Bhattacharjee, chairman, Max Institute of Robotic Joint Replacement, who used advanced robotic technology (CUVIS robotic system) along with a cementless medial pivot cruciate-retaining (CR) implant to restore the patient's mobility.
The implant's design allows natural bone growth around it, eliminating the need for traditional cement and offering better integration, greater joint stability and improved long-term outcomes, Bhattacharjee said.
"This is a global first in robotic joint replacement. The precision enabled by the robot and the use of a cementless implant result in faster recovery and a more natural joint feel for the patient," he claimed.
Speaking about the patient's recovery, Dr Bhattacharjee said, "He was barely able to walk before surgery. But on the day of the operation itself, he managed to walk with assistance. Within just a few days, he was walking independently with renewed confidence."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
City reports four more Covid cases
Mumbai: Maharashtra on Saturday reported four Covid-19 cases, all of which were detected in Mumbai, a health department official said. The state's tally since Jan 1 this year stands at 2,624, while that of Mumbai during this period is 1,043. While 41 people have died of the ailment, including 40 with comorbidities, the recovery count is 2,536. PTI
Hindustan Times
a day ago
- Hindustan Times
Naveen Patnaik returns to Odisha after 21 days after spine surgery in Mumbai
Biju Janata Dal (BJD) president Naveen Patnaik on Saturday returned to Bhubaneswar after fully recovering from his spine surgery for cervical arthritis in Mumbai. Patnaik had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis.(PTI File) Patnaik's special flight landed at the Biju Patnaik International Airport at about 2 pm. He returned to Odisha after 21 days, said BJD senior vice president Debi Prasad Mishra. The former five-time chief minister of Odisha was accorded a ceremonial welcome by the party men and women, who gathered at the airport since morning. The Jai Jagannath slogan rented the air as Patnaik stepped out of the airport. Holding placards and BJD flags, thousands of people stood on both sides of the road leading from the airport to Naveen Niwas, the residence of Patnaik, to welcome and greet their leader. He waved to the people at the airport. Patnaik, the Leader of the Opposition in Odisha Assembly, had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis at Kokilaben Dhirubhai Ambani Hospital in Mumbai on June 22. He was shifted to a private room from the ICU after being kept under observation for two days and was discharged from the hospital on July 7. The surgery was conducted by Dr S Rajasekaran, an orthopaedic surgeon and chairman of Ganga Medical Center and Hospitals in Coimbatore. In Patnaik's absence, the BJD's 15-member committee led by vice-president Debi Mishra was looking after party affairs in the state.
The Print
a day ago
- The Print
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. New Delhi, Jul 12 (PTI) People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. 'But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment,' Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India,' said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. 'We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed,' said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. 'India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care,' Rizwan said. PTI PLB SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
